Overview

To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days

Status:
Completed

Trial end date:
2010-08-01

Target enrollment:

Participant gender:

Summary

To investigate the safety and tolerability of TC-5214 following oral administration of single and multiple ascending doses compared to placebo.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca